

November 12, 2022

To, To,

**BSE Limited**, Listing Department,

25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex,

Mumbai – 400 001 Bandra (East), Mumbai- 400051

Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE | | Series: EQ

Sub: Audio Recording of the Investor/Analyst call on the Un-audited Financial Results (Consolidated and Standalone) for the half year quarter ended September 30, 2022.

In continuation of our letter dated November 7, 2022 and pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), the audio recording of the Investor/Analyst conference call held today i.e. November 12, 2022 on the Un-audited Financial Results (Consolidated and Standalone) of the Company for the half year and quarter ended September 30, 2022 is available on the Company's website at <a href="https://www.camlinfs.com/investorcallrecording">https://www.camlinfs.com/investorcallrecording</a>

The Management was represented by Mr. Ashish Dandekar, Chairman & Managing Director, Mr. Nirmal Momaya, Managing Director and Mr. Santosh Parab, Chief Financial Officer.

Discussions were based on publicly available information. No unpublished price sensitive information (UPSI) was discussed during the interactions.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Thanking You, For Camlin Fine Sciences Limited

**Rahul Sawale Company Secretary** & VP Legal



Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098. CIN: L74100MH1993PLC075361







